| Autor: |
Soni H; Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA., Chiocca EA; Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. eachiocca@bwh.harvard.edu., Bernstock JD; Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. jbernstock@bwh.harvard.edu. |
| Abstrakt: |
Competing Interests: Competing interests: J.D.B. has positions and equity in Pockit Diagnostics Ltd., an equity position in Treovir Inc., and serves on the boards of Centile Bio and NeuroX1. E.A.C. received consulting fees from Thervir, Inc. and has equity options in Bionaut Laboratories, Seneca Therapeutics and Ternalys Therapeutics. E.A.C. is also a co-founder and on the Board of Directors of Ternalys Therapeutics, and a co-inventor of patents on oncolytic viruses owned by his institution and licensed to Candel Therapeutics. H.S. declares no competing interests. |
Full text from SpringerLink